AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21681652 — intervention group
Group type: EXPERIMENTAL
Intervention: MOXI‐AF (0.5% moxifloxacin ophthalmic solution)
Number of subjects: 1180
Study 18778380 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tutorial
Number of subjects: 21
Study 18778380 — intervention group
Group type: COMPARATOR
Intervention: Didactic group
Number of subjects: 21
Study 18778380 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based group
Number of subjects: 21
Study 17175636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 500 ml of 50 g/L fructose daily for 3 days after escharectomy
Number of subjects: 41
Study 17175636 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of glucose 1 day after escharectomy for 3 days
Number of subjects: 41
Study 17175636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 500 ml of 50 g/L fructose
Number of subjects: 41
Study 17175636 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of glucose
Number of subjects: 41
Study 12585341 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 20 mg daily
Number of subjects: 8
Study 12585341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12585341 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 8
Study 10945089 — intervention group
Group type: EXPERIMENTAL
Intervention: HoNOSCA (Health of the Nation Outcome Scales for Children and Adolescents)
Number of subjects: 203
Study 9179087 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (18 ± 1 mg)
Number of subjects: 23
Study 9179087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7866044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (30 mg/kg for 3 days)
Number of subjects: 100
Study 7866044 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (30 mg/kg for 3 days)
Number of subjects: 100
Study 2475722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cifenline (130 mg or 160 mg twice daily)
Number of subjects: 46
Study 2475722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 176876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (12, 16, or 20 g daily)
Number of subjects: 35
Study 176876 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (1, 1.5, or 2 g daily)
Number of subjects: 35
Study 176876 — intervention group
Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 35
Study 30535356 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype-based workflow
Number of subjects: 18
Study 30535356 — intervention group
Group type: COMPARATOR
Intervention: Common computational approach
Number of subjects: 18
Study 29035887 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of Valeriana officinalis extract (valerenic acid 0.8%)
Number of subjects: 15
Study 29035887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (an equal dose of vitamin E)
Number of subjects: 15
Study 26409920 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 0.5% ropivacaine
Number of subjects: 70
Study 26409920 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration with 0.5% ropivacaine
Number of subjects: 70
Study 26409920 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 70
Study 26409920 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration
Number of subjects: 70
Study 24607293 — intervention group
Group type: EXPERIMENTAL
Intervention: melatonin 3 mg/day
Number of subjects: 48
Study 24607293 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 48
Study 22782199 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole, 480 mg, once daily
Number of subjects: 252
Study 22782199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 109 colony-forming units, twice daily
Number of subjects: 252
Study 19254330 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential index (HRV measurement)
Number of subjects: 261
Study 19254330 — intervention group
Group type: EXPERIMENTAL
Intervention: Time and frequency indices of HRV (SDNN, r-MSSD, SDNNIDX, total power, VLF, LF, HF)
Number of subjects: 261
Study 19254330 — intervention group
Group type: EXPERIMENTAL
Intervention: pNN50 and LF/HF
Number of subjects: 261
Study 19254330 — intervention group
Group type: COMPARATOR
Intervention: SDNN, SDNNIDX, total power, LF, LF/HF
Number of subjects: 261
Study 19254330 — intervention group
Group type: COMPARATOR
Intervention: Differential index, pNN50, HF
Number of subjects: 261
Study 17239698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg + fenofibrate 160 mg (EZE/SIMVA + FENO)
Number of subjects: 611
Study 15692328 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO solution
Number of subjects: 20
Study 12670094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic furcation tip
Number of subjects: 15
Study 12670094 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic conventional tip and hand scalers
Number of subjects: 15
Study 9578503 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with a father who smoked (Group B)
Number of subjects: 54
Study 9578503 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with both parents being smokers (Group C)
Number of subjects: 54
Study 9578503 — intervention group
Group type: COMPARATOR
Intervention: Infants with non-smoking parents (Group A)
Number of subjects: 54
Study 1961665 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5.0 mg/kg
Number of subjects: 16
Study 1961665 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2.5 mg/kg
Number of subjects: 16
Study 1961665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 mg. methylcellulose)
Number of subjects: 16
Study 6794592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disodium cromoglycate (DSCG)
Number of subjects: 13
Study 6794592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30641025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored group
Number of subjects: 16
Study 30641025 — intervention group
Group type: COMPARATOR
Intervention: Non-mentored group
Number of subjects: 16
Study 31141730 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment of MAL DL‐PDT
Number of subjects: 31
Study 31141730 — intervention group
Group type: COMPARATOR
Intervention: Two treatments of MAL DL‐PDT (1 week apart)
Number of subjects: 31
Study 31141730 — intervention group
Group type: COMPARATOR
Intervention: Two treatments of MAL DL‐PDT
Number of subjects: 31
Study 28429904 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of lutein for 36 weeks
Number of subjects: 31
Study 28429904 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo for 36 weeks
Number of subjects: 31
Study 26057285 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time control system using EMG signals and historical information
Number of subjects: 7
Study 26057285 — intervention group
Group type: COMPARATOR
Intervention: Real-time control system using mechanical sensor data only
Number of subjects: 7
Study 23561480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 2% soaked gauze for 5 minutes followed by normal saline irrigation
Number of subjects: 49
Study 23561480 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of debridement and skin grafting
Number of subjects: 49
Study 21671489 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (10 Hz, 90% motor threshold) combined with citalopram (20 mg/d)
Number of subjects: 60
Study 21671489 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure combined with citalopram (20 mg/d)
Number of subjects: 60
Study 19489241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with 0.5 microg/ml sufentanil (latent group)
Number of subjects: 360
Study 19489241 — intervention group
Group type: COMPARATOR
Intervention: 0.15% ropivacaine with 0.5 microg/ml sufentanil (active group)
Number of subjects: 360
Study 16221926 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (NE agonist)
Number of subjects: 0
Study 16221926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (DA agonist)
Number of subjects: 0
Study 16221926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (ACh agonist)
Number of subjects: 0
Study 16221926 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (NE antagonist)
Number of subjects: 0
Study 16221926 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (DA antagonist)
Number of subjects: 0
Study 16221926 — intervention group
Group type: COMPARATOR
Intervention: Biperiden (ACh antagonist)
Number of subjects: 0
Study 15330271 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 41
Study 15330271 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 41
Study 15330271 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat enriched diet (SFA)
Number of subjects: 41
Study 11122852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 0
Study 1523161 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal)
Number of subjects: 0
Study 1523161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT, 20 IU intranasal)
Number of subjects: 0
Study 1523161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6208877 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded elastic compression stockings
Number of subjects: 80
Study 30460999 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (FOBT)
Number of subjects: 321311
Study 30460999 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 321311
Study 28328726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleadew cleaning and disinfecting system
Number of subjects: 0
Study 28328726 — intervention group
Group type: COMPARATOR
Intervention: Habitual multipurpose disinfecting system
Number of subjects: 0
Study 27008910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training with an instrumented exercise workstation and functional electrical stimulation for 1 hour per day, 5 days per week for 8 weeks.
Number of subjects: 70
Study 27008910 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus three 15-minute sessions per week of one-to-one hand therapy without functional electrical stimulation.
Number of subjects: 70
Study 24613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with mild AMD (n=30)
Number of subjects: 793
Study 24613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with moderate AMD (n=346)
Number of subjects: 793
Study 24613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with severe AMD (n=462)
Number of subjects: 793
Study 24613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with noncentral geographic atrophy (n=70)
Number of subjects: 793
Study 24613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with advanced AMD (n=324)
Number of subjects: 793
Study 23242726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg)
Number of subjects: 210
Study 23242726 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (15 mg/kg)
Number of subjects: 210
Study 23242726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 20184576 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelox (complex plant extract)
Number of subjects: 124
Study 20184576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 18378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg for 7 days
Number of subjects: 189
Study 18378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg for 7 days
Number of subjects: 189
Study 18378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole coadministration
Number of subjects: 189
Study 18378563 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9(*)3 alleles presence
Number of subjects: 189
Study 15764773 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 200
Study 15764773 — intervention group
Group type: COMPARATOR
Intervention: CABG/CPB
Number of subjects: 200
Study 12572696 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening modalities of demonstrated effectiveness
Number of subjects: 0
Study 12572696 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening
Number of subjects: 0
Study 12572696 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based screening programmes
Number of subjects: 0
Study 10587285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioglycin
Number of subjects: 2
Study 8934867 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control (received a letter by mail plus a complimentary 'EXERCISE' key chain)
Number of subjects: 200
Study 8934867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (received a letter by mail)
Number of subjects: 200
Study 8934867 — intervention group
Group type: COMPARATOR
Intervention: Control (received no intervention)
Number of subjects: 200
Study 1940933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 43
Study 1940933 — intervention group
Group type: COMPARATOR
Intervention: Cementless fixation
Number of subjects: 43
Study 6720317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg terbutaline intramuscularly
Number of subjects: 8
Study 6720317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline intramuscularly
Number of subjects: 8
Study 6720317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline intramuscularly
Number of subjects: 8
Study 6720317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline inhalation
Number of subjects: 8
Study 6720317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30056409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyblade (experimental group)
Number of subjects: 30
Study 30056409 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy (control group)
Number of subjects: 30
Study 29608445 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to HIV and syphilis testing at 300 pathology centers without requiring consultations
Number of subjects: 419
Study 29608445 — intervention group
Group type: COMPARATOR
Intervention: Consultation at every test (control group)
Number of subjects: 419
Study 26854123 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Number of subjects: 331
Study 26854123 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 331
Study 26854123 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (continuation phase)
Number of subjects: 331
Study 26854123 — intervention group
Group type: COMPARATOR
Intervention: MDI to pump therapy (continuation phase)
Number of subjects: 331
Study 26854123 — intervention group
Group type: COMPARATOR
Intervention: Insulin pump therapy and MDI
Number of subjects: 331
Study 24424357 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim, Amgen, 300 μg/1.0 mL)
Number of subjects: 141
Study 24424357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 141
Study 23506652 — intervention group
Group type: EXPERIMENTAL
Intervention: PIFU-PL (plain language Patient Instructions for Use)
Number of subjects: 50
Study 21683527 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 114
Study 21683527 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 114
Study 18178293 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomized children after second vaccination
Number of subjects: 17
Study 18178293 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomized children after third vaccination
Number of subjects: 17
Study 18178293 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomized children
Number of subjects: 17
Study 18178293 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls, n=30
Number of subjects: 17
Study 16455634 — intervention group
Group type: EXPERIMENTAL
Intervention: [188Re]anti‐CD66
Number of subjects: 114
Study 16455634 — intervention group
Group type: COMPARATOR
Intervention: [90Y]anti‐CD66
Number of subjects: 114
Study 14663604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen/LDL-apheresis
Number of subjects: 201
Study 14663604 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (prednisolone, hydroxyethyl starch, pentoxifylin)
Number of subjects: 201
Study 14663604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen/LDL-apheresis in patients with plasma fibrinogen >295 mg/dl
Number of subjects: 201
Study 14663604 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy in patients with plasma fibrinogen >295 mg/dl
Number of subjects: 201
Study 10826426 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 76
Study 10826426 — intervention group
Group type: COMPARATOR
Intervention: Loop colostomy
Number of subjects: 76
Study 10826426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoma care problems
Number of subjects: 76
Study 8880846 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable, as this study is a database creation and not a clinical trial with interventions.
Number of subjects: 8000
Study 1497047 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hyperoxygenation (oxygen-treated group, n = 17)
Number of subjects: 36
Study 1497047 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (n = 19)
Number of subjects: 36
Study 6351364 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 220C
Number of subjects: 2340
Study 6351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippes Loop D
Number of subjects: 2340
Study 6351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper 7
Number of subjects: 2340
Study 6351364 — intervention group
Group type: COMPARATOR
Intervention: All devices
Number of subjects: 2340
Study 31932569 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-participated health coaching for 12 weeks
Number of subjects: 26
Study 31932569 — intervention group
Group type: COMPARATOR
Intervention: Health coaching only for workers
Number of subjects: 26
Study 29385178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 18
Study 29385178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meal
Number of subjects: 18
Study 29385178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) meal
Number of subjects: 18
Study 27090097 — intervention group
Group type: COMPARATOR
Intervention: Single session Brief Intervention/Referral to Treatment (BI/RT)
Number of subjects: 600
Study 27090097 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-session Brief Intervention/Referral to Treatment (BI/RT+)
Number of subjects: 600
Study 27090097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (BI/RT and BI/RT+)
Number of subjects: 600
Study 27090097 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 600
Study 27090097 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation
Number of subjects: 600
Study 25242204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2×500 mg/day)
Number of subjects: 8
Study 25242204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22897461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin monotherapy 40 mg/day (R group)
Number of subjects: 71
Study 22897461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group)
Number of subjects: 71
Study 22897461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day combined with ω-3 fatty acids 2 g/day (Rω group)
Number of subjects: 71
Study 20190066 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based informatics system (PRECARES)
Number of subjects: 689
Study 20190066 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparable third section)
Number of subjects: 689
Study 17033631 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) 40,000 IU weekly intravenous infusion for 12 weeks
Number of subjects: 39
Study 17033631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17033631 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO)
Number of subjects: 39
Study 15875240 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic arc (SPARC) sling
Number of subjects: 62
Study 15875240 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 62
Study 11953541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by an occupational therapist
Number of subjects: 60
Study 11953541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 60
Study 9607691 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinyloestradiol + 150 microg desogestrel for 3 months
Number of subjects: 33
Study 9607691 — intervention group
Group type: COMPARATOR
Intervention: 35 microg ethinyloestradiol + 2 mg cyproterone acetate for 3 months
Number of subjects: 33
Study 8550255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise glucose polymer (G) and placebo during exercise (G/P)
Number of subjects: 5
Study 8550255 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer pre-exercise and during exercise (G/G)
Number of subjects: 5
Study 8550255 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-exercise and during exercise (P/P)
Number of subjects: 5
Study 1965645 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg cicletanine
Number of subjects: 0
Study 1965645 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg cicletanine
Number of subjects: 0
Study 1965645 — intervention group
Group type: COMPARATOR
Intervention: Control (no cicletanine)
Number of subjects: 0